1.
Clin Case Rep
; 5(8): 1258-1260, 2017 08.
Artículo
en Inglés
| MEDLINE
| ID: mdl-28781837
RESUMEN
The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib-resistant patients, as may provide much longer overall survival than previously reported treatments.